A Phase 3 French study, which will be presented at the American Society of Clinical Oncology (ASCO)’s annual meeting at the end of May, demonstrated improved survival rates for those patients who received bevacizumab in addition to the current standard chemotherapy regimen of pemetrexed/cisplatin. Bevacizumab (Avastin® Genentech, Inc.) is an antibody that blocks angiogenesis (blood […]
On Thursday, May 14 at 8PM ET, the Meso Foundation will interview Drs. Evan Alley and Charles Simone of Penn Medicine during a new installment of the Meet the Mesothelioma Experts live teleconference series. The interview will be led by the Meso Foundation’s executive director and expert mesothelioma nurse practitioner Mary Hesdorffer.
This session, titled Focus […]
Watch Mary Hesdorffer, the Meso Foundation’s executive director and mesothelioma expert, in this opening presentation at the 2015 International Symposium on Malignant Mesothelioma. In this video, she discusses the state of mesothelioma research and treatment options. Her discussion begins with a focus on clinical trials. With 92 open clinical trials for mesothelioma, of which 55 […]
The Meso Foundation is optimistic about the results of the Phase 1b trial of pembrolizumab for PD-L1-positive advanced solid tumors, which were announced at the most recent meeting of the American Association for Cancer Research (AACR).
Dr. Evan W. Alley, MD, PhD, co-director of the Penn Mesothelioma and Pleural Program, reported the results of a Phase […]
We are excited to announce that the 2015 recipient of the Meso Foundation’s June Breit and Jocelyn Farrar Outstanding Nurse Award is Joanne Redondo of the Hillman Cancer Center.
In January, we introduced our second annual campaign to choose a recipient of the June Breit and Jocelyn Farrar Outstanding Nurse Award. We began seeking a recipient […]